Gestational Diabetes Market Research Report, By Type (Type A1, Type A2), Administration (Oral, Intravenous), Treatment (Monitoring, Drug Treatment, Non-Pharmacological Treatment), End User (Hospital, Retail Pharmacy) - Forecast till 2030

Gestational Diabetes Market Scenario:

The Gestational Diabetes Market is projected to reach USD 16,040 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030. Diabetes is a metabolic disorder in which the body glucose level is elevated. Gestational diabetes is a temporary or permanent form of diabetes in which the body daoes not produce adequate amounts of insulin to regulate sugar during pregnancy. It may also be called glucose intolerance or carbohydrate intolerance. According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population is suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. According to the American Pregnancy Association, approximately 2-5% of pregnant women develop gestational diabetes; this number may increase to 7-9% of mothers who are more likely to have risk factors. Increasing prevalence of the gestational diabetic population is the major driving factor for the growth of the gestational diabetes market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the gestational diabetes market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the gestational diabetes market. However, lack of awareness among people and cost issues may lead to restrain the growth of the market.

Intended Audience

• Biotechnological institutes


• Pharmaceutical companies


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Medical Research Laboratories 

Figure 1:- Global gestational diabetes market share, by region

    Annual reports, Press release, White paper, Company PresentationSegmentation

The gestational diabetes market is segmented on the basis of types, administration, treatment, and end users.

On the basis of types, the gestational diabetes market is segmented into type A1, type A2 and others.

On the basis of administration, the gestational diabetes market is categorised into oral, intravenous, and other.

On the basis of treatment, the gestational diabetes market is segmented into monitoring, drug treatment, and non-pharmacological treatment. Monitoring is further segmented into urinary glucose testing, oral glucose tolerance test, and others. Drug treatment is subsegmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others

On the basis of end users, the gestational diabetes market is segmented into hospital, retail pharmacy and other.

Regional Analysis

America dominates the gestational diabetes market owing to large patient population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US were diagnosed with high cholesterol level. Increasing cholesterol level and smoking increases the possibility of causing diabetes. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.

Europe is the second largest gestational diabetes market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.

On the other hand, the Middle East & Africa has the least share in the gestational diabetes market due to presence of poor economy especially in Africa region. Majority of the market of this region is hold by Middle East due to well-developed healthcare sector and huge healthcare expenditure.

 

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation 

Key players for gestational diabetes market

Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).

Report Scope:

Report Attribute/Metric	Details
Market Size	USD 16,040 Million
CAGR	7.10%
Base Year	2021
Forecast Period	2022-2030
Historical Data	2020
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Types, Administration, Treatment, and End Users
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).
Key Market Opportunities	New product launches and R&D Amongst major key Players
Key Market Drivers	Increasing prevalence of the gestational diabetic population Increasing obese population Increasing healthcare expenditure Strong encouragement from the government